Schizophrenia (SZ) is a debilitating brain disorder with a complex genetic architecture. Genetic studies, especially recent genome-wide association studies (GWAS), have identified multiple variants (loci) conferring risk to SZ. However, how to efficiently extract meaningful biological information from bulk genetic findings of SZ remains a major challenge. There is a pressing need to integrate multiple layers of data from various sources, eg, genetic findings from GWAS, copy number variations (CNVs), association and linkage studies, gene expression, protein-protein interaction (PPI), co-expression, expression quantitative trait loci (eQTL), and Encyclopedia of DNA Elements (ENCODE) data, to provide a comprehensive resource to facilitate the translation of genetic findings into SZ molecular diagnosis and mechanism study. Here we developed the SZDB database (http://www.szdb.org/), a comprehensive resource for SZ research. SZ genetic data, gene expression data, network-based data, brain eQTL data, and SNP function annotation information were systematically extracted, curated and deposited in SZDB. In-depth analyses and systematic integration were performed to identify top prioritized SZ genes and enriched pathways. Multiple types of data from various layers of SZ research were systematically integrated and deposited in SZDB. In-depth data analyses and integration identified top prioritized SZ genes and enriched pathways. We further showed that genes implicated in SZ are highly co-expressed in human brain and proteins encoded by the prioritized SZ risk genes are significantly interacted. The user-friendly SZDB provides high-confidence candidate variants and genes for further functional characterization. More important, SZDB provides convenient online tools for data search and browse, data integration, and customized data analyses.
Introduction
Schizophrenia (SZ) is a severe mental disorder characterized by abnormal perceptions, incoherent or illogical thoughts, and disorganized speech and behavior. It affects approximately 0.5%-1% of the world populations 1 and is one of the leading causes of disability worldwide. [2] [3] [4] With the substantial morbidity and high mortality, SZ imposes profound impact on patients' quality of life, and significant economic burden on families and society. 4 It is estimated that the overall cost of SZ in the United States in 2002 was $62.7 billion. 5 In Canada, the total cost of SZ was estimated to be 6.85 billion (Canadian dollars) in 2004. 6 The global economic burden of SZ is continuously increasing, which makes SZ an urgent global health issue.
Despite the fact that millions of people are suffering from SZ and the substantial personal and societal costs, current available antipsychotic medications can only alleviate the symptoms of SZ. Moreover, the efficacy of antipsychotic drugs varies greatly among patients (ie, many patients are treatment-resistant). 7, 8 So far, there is no drug or treatment that can completely cure SZ or ensure that there will be no further psychotic episodes. A key reason for this therapeutic conundrum is due to the unknown pathophysiological mechanism of SZ. During the past decades, great efforts have been made to identify the causes of SZ and to develop new drugs and treatments. Though significant progress has been achieved, the etiology of SZ remains largely unknown.
A growing body of evidence strongly suggest that both genetic and environmental factors are involved in the pathophysiology of SZ. 9 Previous studies have shown that environmental factors such as obstetric complications, exposure to influenza viruses during gestation, and prenatal exposure to maternal stress can increase risk of SZ. [10] [11] [12] [13] [14] [15] Though environmental factors have a role in the pathogenesis of SZ, high heritability clearly shows the major role of inherited genetic variants in the etiology of SZ. 16 Family, twin and adoption studies have consistently demonstrated the key role of genetic components in the pathogenesis of SZ. The heritability estimate of SZ is about 0.80, 16 which is higher than most of other complex diseases. 17 To elucidate the genetic susceptibility to SZ, large numbers of linkage and association studies, as well as meta-analyses have been performed, and numerous risk variants, genes, and chromosomal regions have been reported to be associated with SZ. [18] [19] [20] Despite the fact that many promising candidate genes have been identified, the sample sizes are relatively small and the coverage of genetic markers are relatively low in these studies, which limited the identification of credible susceptibility variants and genes. The advent of genome-wide association studies (GWAS) provides critical opportunities to explore the genetic landscape of SZ. In 2008, ZNF804A had been identified as the first gene that reached a genome-wide significant level for SZ. 21 Since then, multiple GWAS have been conducted in world populations and numerous SZ-associated variants and loci were identified. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] A landmark of SZ genetics is the establishment of Psychiatric Genomics Consortium (PGC), which performed the largest GWAS meta-analysis of SZ so far and identified numerous high-confidence genetic risk variants and loci. 36 With the continuous increase of sample size in PGC, novel risk variants and genes can now be identified at unprecedented rates. Despite the great success of GWAS in identifying SZ risk variants, understanding the pathological role of these risk variants in SZ remains a daunting task. First, most of the SZ-associated variants identified by GWAS reside in noncoding regions (with limited annotation and no obvious functional consequence), how these risk variants contribute to SZ risk is largely unknown. There is a growing gap between the identification of SZ risk variants and the extraction of meaningful biological information. Second, besides the common genetic variants (single nucleotide polymorphisms, SNPs) identified by GWAS, other types of genetic variations including rare variants, copy number variation (CNV), and structural genomic variations play a pivotal role in SZ. [37] [38] [39] [40] [41] Therefore, there is a pressing need to integrate data from various genetic studies of SZ to provide a global view of current genetic findings on SZ. Third, systematic integration and in-depth analysis of multi-type data from various sources (eg, genetic and gene expression studies) will help to provide useful guide for further experimental validation and to establish the connection among different types of data. For example, selecting high-confidence candidate gene for further functional validation is challenging due to a large number of genes identified by genetic association studies. Gene prioritization analysis (eg, convergent functional genomics) 42 provides a valuable solution for selecting the candidate genes for experimental verification. Fourth, accumulating evidence imply that common polygenic variation contributes to SZ risk. 22 That is, SZ is likely caused by multiple genes that disrupt one or more molecular pathways. 43, 44 Thus, pathway and network-based analysis is an effective method to identify the molecular pathways dysregulated in SZ and helps with mechanism investigation and drug development. To better understand the genetic architecture of SZ and to facilitate the translation of genetic findings into molecular risk mechanisms for SZ, we developed SZDB, a comprehensive database containing multiple integrative data from various layers of SZ genetic researches. SZDB not only provides a user-friendly web interface for data search, browse and visualize, but also provides in-depth data integration and analysis functions such as SNP functional annotation, spatio-temporal gene expression pattern analysis in human brain, expression quantitative trait loci (eQTL) and network-based (PPI and co-expression) analyses.
Methods

SNP Associations From GWAS of SZ
Several GWAS of SZ have been performed during the past decade. To further increase the statistic power, PGC2 performed the largest meta-analysis of SZ GWAS so far. 36 In brief, genome-wide genotype data of 49 ancestry-matched, nonoverlapping case-control samples and 3 family-based samples of European ancestry were obtained. The total sample size included in the GWAS meta-analysis was 82 315, including 35 476 SZ cases and 46 839 controls. After quality control and SNP imputation, association test was performed separately in each sample and the results were combined and meta-analyzed. More detailed information about sample description, genotyping and statistical analyses can be found in the original paper. 36 We downloaded the summary statistics (SNP associations) of PGC2 from the PGC website (http://www.med.unc.edu). In total, summary statistics of 9 444 230 SNPs were downloaded.
Plotting of Regional Association Signal
To visualize the results of genome-wide association data of PGC2, 36 we utilized the LocusZoom 45 to plot regional association results. The P values of SNPs were downloaded from the PGC website (http://www.med.unc.edu/ pgc/downloads). 36 We downloaded the Hg19 genome assembly and 1000 Genomes population data from http:// locuszoom.sph.umich.edu/locuszoom/.
SNP Function Annotation
Most of the SZ-associated SNPs identified by GWAS lie in noncoding region and are predominately located within putative regulatory elements, 36 suggesting that these variants may confer risk to SZ through affecting gene expression. We took advantage of the recent study by Boyle et al 46 that systematically annotated SNPs in human genome using experimental data sets from ENCODE 47 and other sources. 46, 48 Briefly, high-throughput computational and experimental data sets, including DNase footprinting, binding motif, ChIP-seq, chromatin state, eQTL, as well as other sources were used to predict if a specific SNP has a regulatory potential. To make the results easier to use and understand, a score system was introduced and a corresponding database (RegulomeDB, http://RegulomeDB.org/) was developed by Boyle and coworkers. 46 Lower scores in the RegulomeDB suggest increasing evidence for a variant to be located in a functional region. More detailed information about variant annotation and RegulomeDB database can be found in the original paper. 46 We downloaded the RegulomeDB score data for all SNPs (including genotyped and imputed) analyzed in PGC2 36 and integrated these scores into SZDB. We also annotated the potential functional consequences of the non-synonymous (missense) variants using SIFT 49, 50 and PolyPhen-2 51 , 2 extensively used prediction tools to conduct in silico functional prediction of non-synonymous (missense) variants.
Extraction and Compilation of SZ Candidate Genes
Previous studies (including genetic linkage and association studies, 18, 19 GWAS, 36 integrative studies such as convergent functional genomics (CFG) 42 and Sherlock integrative analysis, 52 and whole exome sequencing studies 53, 54 ) have identified numerous SZ candidate genes. We systematically extracted and compiled a comprehensive list of SZ candidate genes from these studies. Based on the study type, SZ candidate genes were classified into the following categories:
(1) Genes identified by genetic linkage and association studies. 58 developed a statistical framework (named Sherlock) to identify disease-associated genes through matching eQTL and SNP associations from GWAS. We performed integrative analysis using Sherlock and identified 12 promising SZ candidate genes. 52 We integrated these 12 genes into SZDB. (6) Genes differentially expressed in SZ cases. Dysregulation of gene expression has a key role in SZ pathogenesis. To detect genes that are differentially expressed between SZ patients and healthy controls, many large-scale gene expression studies have been performed. We downloaded 5 microarray datasets (which used brain tissues from SZ patients and controls) from the gene expression omnibus (GEO; [http://www.ncbi.nlm.nih.gov/geo/]), including GSE53987 (contains 3 brain tissues: prefrontal cortex, striatum and hippocampus; a total of 114 samples), 59 GSE12649 (prefrontal cortex; a total of 69 postmortem brains samples), 60 GSE21138 (prefrontal cortex; a total of 59 postmortem brains samples), 61 GSE35978 (cerebellum and parietal cortex brain; a total of 195 samples), 62 and GSE62191 (frontal cortex; a total of 59 samples). 63 We re-analyzed these microarray datasets, and top 1% differentially expressed genes in SZ cases and controls were integrated into SZDB. The differentially expressed genes identified by RNA sequencing (RNA-seq) 64 were also integrated into SZDB.
(7) Genes identified by Pascal gene-based test. The gene-based analysis is a strategy to improve statistical power and gain biological insight. 65 Through this test, one can get an overview from the gene and pathway level rather than the SNP level. Here we used the gene-based test Pathway scoring algorithm (Pascal) 65 to integrate PGC2 GWAS data. A total of 343 genes with P-values lower than 10 -6 were included in the SZDB (supplementary table S10). (8) Genes identified by whole exome sequencing.
Accumulating evidence suggest that de novo mutations and rare disruptive mutations play an important role in SZ pathogenesis. Recently, Fromer et al 54 performed the largest exome sequencing study of de novo mutations in SZ and they found that de novo mutations in SZ are overrepresented in synaptic networks. We integrated genes (supplementary table S11) that carrying de novo mutations (including coding and canonical splice site variants) in SZ probands from the study of Fromer et al 54 into SZDB. In addition, Purcell et al 53 identified numerous genes that contain rare disruptive mutations in SZ cases through exome sequencing. We also integrated the genes (supplementary table S12) identified by Purcell et al 53 into SZDB. (9) Genes differentially methylated in SZ. In addition to genetic components, environmental factors may also play an important role in SZ. DNA methylation is a common epigenetic modification that is influenced by environmental factors, and recent studies 66, 67 have identified multiple differentially methylated genomic regions (or genes) among SZ cases and healthy controls. We integrated the differentially methylated genes identified by Montano et al 67 and Aberg et al 66 into SZDB. In addition, we also integrated the methylation quantitative trait loci from study of Hannon et al 68 into SZDB.
In-depth Data Analysis and Systematic Integration
Based on the above comprehensive data/ gene lists from various sources, we carried out the following in-depth data analyses and systematic integration:
(1) eQTL analysis. Genetic variants affecting gene expression in brain tissues may confer risk of SZ. To investigate if genome-wide significant SNPs identified by PGC2 are associated with gene expression in human brain, we downloaded genome-wide expression and genotype data from the study of Myers et al, 69 which included 193 neuropathologically normal human brain samples. The association between each SNP and transcript was assessed by using PLINK, 70 as described in the study of Myers et al. 69 In total, we assessed correlations among 366 140 SNPs and the expression of 14 078 transcripts. Briefly, before the analysis, rank-invariant normalized expression data were log 10 transformed, and missing data were encoded as missing, not as a zero level of expression. We excluded transcripts that were expressed in less than 5% of the series from the analysis. The following minimum SNP cut-off values were used: per sample call rate at least 90%, per SNP call rate at least 90%, per SNP minor allele frequency of at least 1%, and lack of significance (P > .05) for the Hardy-Weinberg equilibrium tests. Only those pairs with transcriptspecific empirical P values ≤ .05 were retained. SNP position and gene position were based on the Hg19 genome assembly. (2) Spatio-temporal expression pattern analysis. A pivotal step to elucidate the role of risk genes in SZ pathogenesis is to understand the spatio-temporal expression pattern of risk genes in brain. To investigate if SZ risk genes are preferentially expressed in specific brain tissues (eg, prefrontal cortex and hippocampus) and at specific developmental stages (eg, fetal and postnatal), we performed spatio-temporal gene expression pattern analysis using the RNAseq based gene expression data from the BrainSpan: Atlas of the Developing Human Brain (http://www. brainspan.org). 71 These expression data were from 16 brain regions (a total of 42 postmortem brains) that spanned 15 consecutive periods of neurodevelopment and adulthood from 8 post-conceptual weeks (PCW) to 40 years. The data were partitioned into different developmental stages and subsets of brain regions as described by Willsey et al. 72 Data processing, quality control and statistical analyses were performed as described previously. 73 In addition to expression data from the BrainSpan, 71 we also downloaded expression data from the BrainCloud (http:// braincloud.jhmi.edu/), 74 which contains gene expression data from prefrontal cortex. The developmental stages were also partitioned into 15 periods. More detailed information about the BrainCloud can be found in the original study 74 and the SZDB website (http://www.szdb.org/index.html). (3) Co-expression analysis. Recent study suggested that SZ risk genes are significantly co-expressed in patterns specific to developmental stage and neuroanatomical structure. 73 Therefore, co-expression analysis may help to prioritize SZ candidate genes from largescale genetic studies (eg, GWAS or transcriptome). To explore if SZ risk genes were co-expressed in specific brain regions at specific developmental stages, we performed gene co-expression analyses using the RNA-seq based expression data from the BrainSpan: Atlas of the Developing Human Brain (http://www. brainspan.org/). 71 Briefly, we divided the tissues from the BrainSpan atlas into 4 anatomic regions and 15 developmental stages as described by Willsey et al 72 and Gilman et al. 75 The 4 anatomic regions are: (1) V1C-STC cluster (V1C, ITC, IPC, A1C, and STC); (2) Prefrontal and primary motor-somatosensory cortex or M1C-S1C cluster (M1C, S1C, VFC, MFC, DFC, and OFC); Pearson correlation coefficients were calculated in each brain region across developmental stages as described previously. 72, 73 Only gene pair with a Pearson correlation coefficient equal or bigger than 0.8 was retained. (4) Protein-protein interaction (PPI) analysis. Accumulating evidence suggest that proteins involved in the same disease are more likely to interact with each other (ie, guilt-by-association). 76, 77 We had showed that SZ risk genes encode an highly interconnected network, 78, 79 implying PPI information may help to prioritize SZ candidate genes. To explore if proteins encoded by SZ candidate genes are physically interacted with proteins encoded by other genes (including SZ risk genes and others), we downloaded PPI data from InWeb, a well-characterized PPI database developed by Lage et al. 80, 81 Genes directly interact with SZ genes were regarded as the first-degree interaction genes. (5) Analysis of differentially expressed genes. Genes differentially expressed in SZ cases and healthy controls may play a pivotal role in the etiology of SZ. Though multiple gene expression studies have been performed to identify differentially expressed genes in SZ, [59] [60] [61] [62] [63] we noticed that only limited overlapping genes were identified among different studies. To compare the differentially expressed from different studies, we preformed differentially expression analyses using microarray datasets from GEO. The main inclusion criteria are as follows: First, GEO datasets with a relatively large sample size (more than 20 SZ cases) were selected. Second, GEO datasets using brain tissues (including prefrontal cortex, hippocampus, and striatum) were given higher priority. Third, GEO datasets that contain genome-wide gene expression data were selected. It should be noted that only limited expression datasets are public available and can be downloaded from GEO. Based on these criteria, we selected 5 GEO datasets [59] [60] [61] [62] [63] for differential expression analysis. GEO2R (http://www. ncbi.nlm.nih.gov/geo/geo2r/), which uses limma (Linear Models for Microarray Analysis) in R package (an Empirical Bayes method), was used to analyze differentially expressed genes. GEO2R includes the following steps: (1) Load series and platform data from GEO; (2) Group names for all samples; (3) Transform expression data by log2 (if the data were not transformed, auto-detect by GEO2R); (4) Set up the data and proceed with analysis; (5) Load NCBI platform annotation; (6) Replace original platform annotation. To visualize these results, we used the jQuery plugin plotly (https://plot.ly/javascript/) to draw a boxplot for every gene in SZ cases and controls. We also downloaded the differentially expressed genes (a total of 798 genes) identified by the RNAseq 64 and integrated these results into SZDB. (6) Co-expression module analysis. To explore if SZ risk genes show similar expression pattern during cortical development, we performed co-expression network analysis using the RNA-seq based expression data from the BrainSpan. 71 Signed weighted gene co-expression network analysis was performed as previously described. 82 (7) Gene-based analysis. Currently, most of the GWAS tested the association between a trait and individual genetic variant (usually SNP). Gene-based method is a useful complement to GWAS as it considers association between a trait and all variants (eg, SNPs) within a gene rather than each marker individually. To identify the genes that are associated with SZ at the gene level, we performed gene-based analysis using the Pascal software (summary statistics, ie, SNP P values from PGC2 were used as input). 65 More detailed information can be found in the supplementary material.
Prioritization of SZ Risk Genes
We used an arbitrary cumulative scoring method to prioritize SZ risk genes. The rationale of our method assumed that SZ-associated gene may be detected in several independent studies (or datasets). For example, if a specific gene was identified to be associated with SZ in genetic studies and gene expression study also showed that this gene is dysregulated in SZ cases, we would score this gene as a promising SZ candidate gene. More detailed information about this polyevidence scoring approach can be found in the paper of Ayalew et al 42 in which they identified promising SZ candidate genes through integrating multiple lines of evidence from different SZ researches. We took advantage of the following lines of evidence to prioritize SZ candidate genes in SZDB:
(1) Genes identified by GWAS. If a gene was reported to be associated with SZ in GWAS, the total score of this gene rises by 1 point. (2) Genes identified by genetic linkage and association studies. If a gene was reported to be associated with SZ in previous genetic linkage or association studies, the total score of this gene rises by 1 point. We summed up all scores for each gene and those genes with a score ≥2 were regarded as the prioritized genes (supplementary table S13).
Drug Target Identification
We explored whether the top 29 prioritized genes in SZDB are drug targets through using the Drug-Gene interaction database (http://dgidb.genome.wustl.edu/) 83 and the list of 1030 druggable genes compiled by Rask-Andersen et al. 83 The druggable gene list by Rask-Andersen et al 83 was developed by systematically integration of public available druggable targets resources, including the DrugBank database (http://www.drugbank.ca), 84 the Drugs@FDA database (http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/), and the Drugs in Clinical Trials Database (http://www.centerwatch.com).
Results
Database Overview
On the basis of comprehensive data collection and curation, we performed in-depth data analysis and systematic integration and included all these results in the SZDB. Therefore, SZDB not only contains genetic risk variants and susceptibility genes for SZ, but also provides a demonstration of the in-depth analytical results, such as SNP function annotation, eQTL, spatio-temporal expression and co-expression, and PPI data. Specifically, SZDB integrates powerful online analysis tools and users can easily perform custom analyses such as eQTL, PPI, co-expression and spatiotemporal expression pattern analyses (figure 1). All of the preprocessed datasets can be freely downloaded at SZDB (http://www.szdb.org/download.html). The userfriendly web interface of the SZDB contains 3 core modules: Search module, Analysis and Tools module, and Genes module.
(1) Search module. This module provides a powerful search engine for SNP and gene query. Users can input interested SNPs and genes in the search bar. Multiple search items (eg, a set of interested SNPs or genes) are allowed for single query. For SNP query, SZDB will generate a detailed report (supplementary figure  S1 ), including chromosomal location based on the Hg19 genome assembly and corresponding genomic coordinates of the query SNP, SNP alleles (polymorphism), SNP location in gene (flanking or nearby genes of the query SNP), SNP type (eg, synonymous or non-synonymous substitution), association significance (OR and P value) with SZ (from PGC2 36 ), eQTL (genes whose expression are associated with the query SNP), 69 regulatory potential (RegulomeDB score 46, 48 ). If the query SNP is a non-synonymous SNP, SZDB will also predict the potential impact of amino acid change on protein structure and function using SIFT 49, 50 and PolyPhen-2. 51 To visualize the association significance between the query SNP and SZ, a LocusZoom link for the query SNP is provided (supplementary figure S1). The LocusZoom generates and plots the regional association results between the query SNP (including SNPs that are located 200 kb up and downstream of the query SNP) and SZ using GWAS data from PGC2. 36 The query SNP is highlighted in the LocusZoom results, so the users can evaluate if the query SNP has the smallest association significance (P value) with SZ. For gene query, SZDB will return a "Results" page which includes the Entrez gene id, genomic coordinate, cytogenetic location, and brief description of the query gene (supplementary figure S2) . Of note, a LocusZoom link for the query gene is also provided, and the users can download and browse the association significance between SNPs located in this gene and SZ (based on PGC2 data 36 ; supplementary figure S3). Through using the LocusZoom, the users can get an overview about the association between the query gene and SZ (based on PGC2 data 36 ). The most significant SNP is highlighted in the LocusZoom results (supplementary figure S3) . Moreover, SZDB provides the differentially expressed genes in SZ cases and healthy controls. (2) Analysis and Tools module. This is the most important and useful module. Results from our in-depth analyses were integrated by this module. In this module, users can perform customized analyses, including co-expression analysis, spatio-temporal expression pattern analysis, protein-protein interaction analysis, association analysis, and eQTL analysis. Detailed descriptions for each analysis are as follows: (a) Co-expression analysis. The co-expression analysis can provide exploratory data for candidate gene prioritization and suggestion for more work (eg, functional experiments) to validate if the candidate gene contributes to SZ pathogenesis. Users can explore if a specific gene (or multiple genes) is significantly coexpressed with other genes in a specific brain region at a specific developmental stage (supplementary figure  S4 ). For each input gene, SZDB will return the genes that have the most significant co-expression correlation coefficient (default Pearson correlation coefficient ≥ 0.8) with the input gene. (b) Spatio-temporal expression pattern analysis. Two well-characterized expression datasets 74, 85 were used to construct the spatio-temporal expression pattern of SZ risk genes. Multiple genes are allowed as input for a single query. For each query, SZDB generates the spatio-temporal plot of the query genes. The average expression level of all genes is also calculated and displayed. As the expression data from the BrainCloud 74 contains only one brain tissue (prefrontal cortex), the default mode will calculate the temporal expression patterns of the SZ risk genes in prefrontal cortex. For the Brainspan, 71 users can select different brain regions. Users can conduct customized analysis to examine the spario-temporal expression pattern of the query genes (supplementary figure S5) . (c) PPI analysis. For a specific input protein (or proteins), SZDB extracts all of the proteins that interacted with the query protein (supplementary figure S6) . Multiple proteins are allowed as input for a single query. For visualization, SZDB draws the PPI plot based on the interactions among the input proteins. (d) Regional association plot and linkage disequilibrium analysis. To visualize the association results, SZDB generates regional association plot (supplementary figure S3) . Users can extract the associations (P values) between genetic variants located in a specific chromosomal region and SZ using the PGC2 GWAS data. 36 Three types of query, including SNP, gene, and region are allowed. Users first input the interested gene (SNP or region), then select the flanking region (from several to hundreds kb). SZDB generates the regional association plot and highlights the most significant SNP in the queried region. (e) eQTL analysis. We integrated brain eQTL data from Myers et al 69 into SZDB and users can perform SNP or gene query. For SNP query, SZDB will carry out the eQTL analysis to identify the gene (or genes) whose expression is associated with the query SNP. For gene query, SZDB will extract the SNP (or SNPs) that is associated with the expression of the query gene (supplementary figure S7) . (3) Genes module. Multiple SZ candidate genes have been identified by different methods, including genetic linkage and association studies, differential gene expression studies, convergent functional genomics, Sherlock integrative analysis and so on. Currently, SZ candidate genes from 9 resources were collated and integrated into SZDB: (a) Genes frequently affected by CNVs in SZ cases; (b) Genes identified by SZ GWAS; (c) Genes identified by genetic linkage and association studies; (d) Genes identified by convergent functional genomics (CFG); (e) Genes identified by Sherlock integrative analysis; and (f) Genes differentially expressed in SZ cases and controls; (g) Genes identified by the gene-based test (Pascal) 65 ; (h) Genes identified by whole exome sequencing; and (i) Genes differentially methylated in SZ cases compared with controls. Users can perform customized queries to retrieve these genes.
Prioritized SZ Genes, Enriched Pathways and Drug Targets
In addition to providing a user-friendly online resources and powerful search and analysis tools for users, we also ranked SZ risk genes through using a cumulative scoring strategy (see methods). Polyevidence scoring identified 29 top prioritized SZ candidate genes that have a final score of 3 and above (figure 2 and supplementary table S13). Among these top prioritized genes, 3 (DRD2, PGBD1 and DOC2A) have the highest final score (4 points, ie, 4 lines of evidence support these genes may be associated with SZ), suggesting that these 3 genes may represent promising SZ risk genes. We performed the pathway analysis 86, 87 using genes that have a polyevidence score of 2 and above and identified significant enriched pathways, including synaptic transmission, dopamine metabolic process and ion channel activity (table 1) .
To explore if the top prioritized genes in SZDB are drug targets, we examined the Drug-Gene interaction database 83 and the druggable gene list of RaskAndersen et al. 83 We found that 7 of the top 29 genes prioritized in SZDB database are drug targets, including DRD2, BDNF, COMT, CNR1, GRIA1, SLC1A2, and SRR (supplementary table S14). Of note, DRD2 is the most intensively studied gene and is the target of most of drugs. Fig. 2 . Polyevidence scoring strategy and distribution of top prioritized schizophrenia risk genes on human genome. Schizophrenia risk genes were collected from 7 different sources, including genetic study (genome-wide association studies [GWAS] , linkage and association, copy number variations [CNVs]), gene-based analysis, gene expression study, convergent functional genomics, sherlock integrative analysis, and differentially expressed genes in schizophrenia cases and controls. Evidence from these sources was integrated and genes were scored based on their presence in these sources.
Genes Implicated in SZ are Highly Co-expressed in Human Brain
On the basis of whole-genome transcriptomic data from the BrainSpan (http://www.brainspan.org), 71 we constructed gene co-expression networks by applying signed weighted gene co-expression network analysis (supplementary methods). In total, we identified 23 co-expression modules (figure 3). To further explore if SZ candidate genes are enriched in specific co-expression modules, we used 2 datasets of SZ candidate genes. The first dataset included the genes identified by recent GWAS of SZ (supplementary table S7). The second dataset included genes from our prioritized SZ candidate genes (ie, genes with a ployevidence score of 2 and above; supplementary table S13). We found that SZ candidate genes from GWAS are significantly enriched in co-expression module 2 (M2) (P = .0083) and M5 (P = .0079; figure 3 ). Intriguingly, genes from our polyevidence scoring were also significantly enriched in M2 (P = .018) and M5 (P = .019). These results suggested that SZ candidate genes are highly co-expressed in human brain.
Proteins Encoded by Prioritized SZ Risk Genes are Significantly Interacted
We performed PPI analysis (detailed analysis procedure can be found in our previous study 78 ) using the prioritized SZ genes from SZDB (the genes that have a final score of 2 and above; supplementary table S13). We found that proteins encoded by prioritized SZ risk genes are significantly interacted (P < .05) and formed a densely interconnected PPI network (figure 4). This result further supported our previous findings 78 and suggested that perturbations of common underlying molecular processes or pathways modulate risk to SZ.
Discussion
In recent years, significant progresses have been made to dissect the genetic architecture of SZ. Multiple highly-significant risk variants have been successfully identified by GWAS. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Nevertheless, pinpointing the causal risk variant(s) remains a major challenge. In addition to risk genes identified by GWAS, other promising SZ candidate genes have also been revealed by other approaches, such as genetic linkage and association, 18 gene expression study, convergent functional genomics, 42 Sherlock integrative analysis. 52 With the increase of sample size and improvement of research approaches, novel SZ risk variants and genes are continuously being identified. Though a large number of risk variants and loci have been identified, the pathophysiology of SZ remains largely unknown. Evidently, it is the time to systematically integrate multi-type data from various studies and to harvest meaningful biological information from genetic findings of SZ. Therefore, we developed the SZDB, a comprehensive database that integrates multi-type resources from different layers of SZ researches, to fill the lacuna.
Compared with other SZ databases such as the SZGene 20 and SZGR, 55 the SZDB has several advantages. First, the SZ risk genes included in the SZGene and SZGR were mainly based on genetic linkage and association studies, Fig. 4 . Proteins encoded by prioritized schizophrenia risk genes form a densely interconnected protein-protein interaction (PPI) network. By using the high-confidence PPI data from InWeb, proteins encoded by prioritized schizophrenia risk genes (that have a final score of 2 and above) were used to construct the PPI network. Proteins encoded by prioritized schizophrenia risk genes are shown. and these databases were not updated since the establishment in 2008 and 2010, respectively. Moreover, we found that the SZGR could not be even accessible during the reviewing of this manuscript. We noticed that the SZGR was recently moved to a new website (https://bioinfo.uth. edu/SZGR/). We did not check the content of the new website of the SZGR, but genes identified by GWAS and other integrative analyses such as convergent functional genomics 42 and Sherlock 52 integrative analysis were not included in the SZGene and the old SZGR databases. Second, the SZDB has a powerful analysis module and users can perform customized analysis, including eQTL, PPI, co-expression, spatio-temporal expression pattern analyses, to name a few. Third, on the basis of multi-type data from various resources, in-depth data integration was conducted and top SZ risk genes were prioritized in the SZDB. Interestingly, we noted that DRD2 was among the top prioritized genes and had the highest final scores. Dysregulation of the dopamine system function has been well characterized in SZ and almost all available antipsychotic drugs exert their main therapeutic effects though the blockade of DRD2. [88] [89] [90] [91] The top prioritized genes thus represent promising SZ risk genes which might be worthy of further functional characterization. Fourth, the SZDB will be updated periodically to keep up with the research progress. With the use of new technologies and analysis methods, novel SZ risk variants and genes are continuously being identified. These latest findings will be integrated into SZDB periodically.
This study has several limitations. First, we used a simple and arbitrary scoring algorithm to prioritize the promising SZ candidate genes from diverse sources (eg, genetic and gene expression studies). Though this scoring system is simple and operational, it ignores the potential overlapping between the sources used for scoring. For example, genes identified by convergent functional genomics (CFG) 42 also integrated information from genetic and gene expression studies. Second, we treated all evidence from different sources equally. Nevertheless, genes identified by GWAS represent the high-confidence SZ candidate genes, therefore, these genes should be given higher weight than genes identified by linkage or association study. These limitations can be addressed through developing an appropriate scoring algorithm in the future.
In conclusion, the SZDB aims to provide a comprehensive resource for SZ genetic research. To the best of our knowledge, SZDB is the most comprehensive SZ genetic database that integrates multiple layers of data from various sources so far. With more genes being identified and more data resources being available, SZDB will be updated every 6 months to maintain the up-to-date resources. The SZDB will integrate more types of data in future, including large-scale data from whole-genome sequencing, tissue-specific PPI interactions, gene expression studies from RNA sequencing. Evidence from epigenetics and animal models will also be integrated into SZDB in future. The ultimate goal of SZDB is to provide a one-stop service for SZ researchers, and they can find most of the information they wanted in the SZDB. With the increase of new genes and integration of more data type, the SZDB will become more powerful. We hope the SZDB will facilitate the translation of genetic findings into molecular risk mechanisms for SZ, and ultimately to the improvement of disease diagnosis and treatment.
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